bioAffinity Technologies (NASDAQ:BIAF) Announces Quarterly Earnings Results

bioAffinity Technologies (NASDAQ:BIAF) announced its quarterly earnings data on Friday. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.40) by $1.59, FiscalAI reports. The company had revenue of $1.35 million for the quarter, compared to analysts’ expectations of $1.48 million. bioAffinity Technologies had a negative net margin of 241.93% and a negative return on equity of 301.67%.

bioAffinity Technologies Stock Performance

NASDAQ:BIAF opened at $2.03 on Friday. The company has a quick ratio of 2.58, a current ratio of 2.60 and a debt-to-equity ratio of 0.08. bioAffinity Technologies has a fifty-two week low of $0.69 and a fifty-two week high of $15.00. The stock has a market cap of $9.13 million, a PE ratio of -0.17 and a beta of -1.19. The firm’s fifty day simple moving average is $2.60 and its 200-day simple moving average is $1.90.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Weiss Ratings cut shares of bioAffinity Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 22nd. Wall Street Zen raised shares of bioAffinity Technologies to a “hold” rating in a research note on Saturday, April 4th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Investors Weigh In On bioAffinity Technologies

Institutional investors and hedge funds have recently made changes to their positions in the business. Sabby Management LLC purchased a new stake in shares of bioAffinity Technologies in the 3rd quarter worth about $719,000. Scientech Research LLC purchased a new stake in shares of bioAffinity Technologies in the 3rd quarter worth about $49,000. Geode Capital Management LLC purchased a new stake in shares of bioAffinity Technologies in the 4th quarter worth about $36,000. Finally, J. Safra Sarasin Holding AG purchased a new stake in shares of bioAffinity Technologies in the 1st quarter worth about $164,000. 1.64% of the stock is currently owned by hedge funds and other institutional investors.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.